Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(17%)
Results Posted
100%(1 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_1
3
50%
Ph phase_2
3
50%

Phase Distribution

3

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
3(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)
Other(3)

Detailed Status

unknown3
Completed1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (50.0%)
Phase 23 (50.0%)

Trials by Status

completed117%
terminated117%
unknown350%
recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
recruitingphase_2

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

NCT06340711
terminatedphase_2

Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease

NCT04685499
completedphase_1

Special Combination of OBP-301 and Pembrolizumab

NCT03172819
unknownphase_2

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

NCT03190824
unknownphase_1

A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer

NCT03213054
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06340711Phase 2

Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Recruiting
NCT04685499Phase 2

Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease

Terminated
NCT03172819Phase 1

Special Combination of OBP-301 and Pembrolizumab

Completed
NCT03190824Phase 2

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

Unknown
NCT03213054Phase 1

A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer

Unknown
NCT02293850Phase 1

Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6